GlassScriptPhysician profile
Jennifer E Wiley
NPI 1821660978
$1,463.70
in general payments reported to CMS, 2019-2025
26 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.98 · 2022: $92.38 · 2023: $429 · 2024: $385 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.44 | 2022-2025 | |
| Corcept Therapeutics | $224.78 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $167.52 | 2021-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $87.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $83.77 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $63.20 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $61.41 | 2023-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $55.58 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $39.18 | 2023 | |
| Indivior INC. | $35.18 | 2024-2025 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.15 | 2022-2023 | Jardiance |
| Pfizer INC. | $35.11 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $34.99 | 2025 | |
| Daiichi Sankyo INC. | $32.16 | 2021-2022 | |
| Alkermes, INC. | $27.58 | 2025 | Vivitrol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $24.24 | 2025 | Fanapt |
| Medtronic, INC. | $19.90 | 2024 | Minimed 780g |
| Abbott Laboratories | $19.53 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.14 | 2025 | Xifaxan |
| Mylan Specialty L.P. | $18.83 | 2024 | Yupelri |
| Verona Pharma, INC. | $18.15 | 2025 | Ohtuvayre |
| Dexcom, INC. | $14.60 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.86 | 2024 | Caplyta |
| Amneal Pharmaceuticals LLC | $13.84 | 2024 | Unithroid |
| Scilex Pharmaceuticals INC. | $13.22 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.